Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas
Primary Purpose
Perianal Fistula, Adipose Tissue, Tissue Transplantation
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Injection of autologous adipose tissue in anal fistula
Sponsored by
About this trial
This is an interventional treatment trial for Perianal Fistula focused on measuring autologous adipose tissue, mesenchymal stem cells, perianal fistula
Eligibility Criteria
Inclusion Criteria:
- high trans-sphincteric fistulas
- fistula confirmed and classified by an MRI.
- seton (> 6 weeks) prior to fat injection
- informed, written consent.
Exclusion Criteria:
Anovaginal fistula
- Active sepsis
- IBD, immunodeficiency, prior pelvic irradiation and malignancy
- Insulin dependent diabetes
- More than 4 prior attempts of fistula closure
- Tobacco smoking or nicotine substitution 8 weeks prior to fat injection.
- Pregnancy
- Psychiatric disorders
- BMI ≥ 35 or BMI<20
- Active tuberculosis
- Patient less than 18 years
- Unable to undergo MRI
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Injection with adipose tissue
Arm Description
Injection of freshly collected autologous adipose tissue
Outcomes
Primary Outcome Measures
Investigation of cell proliferation of AT-MSCs
Cell proliferation of AT-MSCs evaluated as number of cells/per day
Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte
Differentiation potential of AT-MSCs: to differentiate into adipocyte measured by Oil-Red O staining and gene expression of adipogenic markers (PPARg and LPL normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast
Differentiation potential of AT-MSCs: to differentiate into osteoblast measured by Alizarin S staining and gene expression of osteogenic markers (BGALP and RUNX2 normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
Measurement of gene expression profile of AT-MSCs
Gene expression of proinflammatory (NFKB, TNFa, IL1B, IL6) and senescence associated molecules(CDKN2A, TP53, TGFB1, VEGFA, IFNG, IL6) of AT-MSCs in relation to the outcome of fistula treatment (i.e. comparison between responders and non-responders). The data are normalized to housekeeping gene beta actin (arbitrary units)
Secondary Outcome Measures
Healing of anal fistula after treatment
Clinical healing defined as closure of the internal and external fistula opening and no discharge evaluated as success rate of the healing in (%)
Evaluation of fistula healing after treatment
A combination of Clinical and MRI healing defined as closure of the internal and external fistula opening and no discharge and no fluid filled fistula tracts on evaluated as success rate of the healing in (%)
Functional gastroenterological outcome after treatment
Anal continence evaluated as the St. Mark's Score (0-24)
Defecation disorder evaluation after treatment
Defecation disorders evaluated as Altomare Obstructed Defecation Score (0-31)
Functional urological outcome after treatment
Urinary incontinence evaluated as ICIQ-UI-SF (0-21)
Full Information
NCT ID
NCT04834609
First Posted
March 22, 2021
Last Updated
April 6, 2021
Sponsor
University of Aarhus
Collaborators
University of Southern Denmark, UiT The Arctic University of Norway
1. Study Identification
Unique Protocol Identification Number
NCT04834609
Brief Title
Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas
Official Title
Identification of Molecular Differences of Adipose-derived Mesenchymal Stem Cells Between Non- Responders and Responders in Treatment of Transsphincteric Perianal Fistulas Using Autologous Fat Graft Injection
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
January 2015 (Actual)
Primary Completion Date
October 2017 (Actual)
Study Completion Date
February 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
University of Southern Denmark, UiT The Arctic University of Norway
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study investigated the cellular and molecular characteristics of AT-MSCs obtained from autologous AT therapy in patients with high transphincteric perianal fistulas of crytoglandular origin. Adipose tissue was injected into anal fistulas. Characteristics of adipose tissue mesenchymal stemcells (AT-MSC) was investigated and compared in patients with fistula that healed after the treatment (responders) to patients who failed to heal (non-responders)
Detailed Description
Injection with allogene or autologous stem cells has been reported to be efficient treatment of perianal fistulas. An alternative to this treatment could be injection with freshly collected autologous adipose tissue. In this study 27 patients with cryptoglandular anal fistulas were treated with freshly collected autologous adipose tissue.A clinical assessment of the patient prior to inclusion was undertaken and a loose seton placed for at least 6 weeks prior to fat injection. An MRI of the pelvis was performed before inclusion. Fistulas with secondary tracts and/or cavities were excluded. The operation was performed in one procedure including liposuction and injection of adipose tissue. A sample of adipose tissue from all 27 patients was analyzed. AT-MSCs were isolated and characterized using cellular and molecular analyses. Clinical and MRI-scanning evaluation of fistula healing and evaluation of ano-rectal function was performed after 6 months. AT-MSCs phenotype was compared between responders and non-responders with respect to fistula healing. The evaluation of the AT-MSCs was performed in a blinded manner.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Perianal Fistula, Adipose Tissue, Tissue Transplantation
Keywords
autologous adipose tissue, mesenchymal stem cells, perianal fistula
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Characterisation of adipose tissue (AT-MSCs) was performed blinded to the result of the treatment responder/non-responder
Allocation
N/A
Enrollment
27 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Injection with adipose tissue
Arm Type
Experimental
Arm Description
Injection of freshly collected autologous adipose tissue
Intervention Type
Procedure
Intervention Name(s)
Injection of autologous adipose tissue in anal fistula
Primary Outcome Measure Information:
Title
Investigation of cell proliferation of AT-MSCs
Description
Cell proliferation of AT-MSCs evaluated as number of cells/per day
Time Frame
At start of treatment
Title
Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte
Description
Differentiation potential of AT-MSCs: to differentiate into adipocyte measured by Oil-Red O staining and gene expression of adipogenic markers (PPARg and LPL normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
Time Frame
At start of treatment
Title
Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast
Description
Differentiation potential of AT-MSCs: to differentiate into osteoblast measured by Alizarin S staining and gene expression of osteogenic markers (BGALP and RUNX2 normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
Time Frame
At start of treatment
Title
Measurement of gene expression profile of AT-MSCs
Description
Gene expression of proinflammatory (NFKB, TNFa, IL1B, IL6) and senescence associated molecules(CDKN2A, TP53, TGFB1, VEGFA, IFNG, IL6) of AT-MSCs in relation to the outcome of fistula treatment (i.e. comparison between responders and non-responders). The data are normalized to housekeeping gene beta actin (arbitrary units)
Time Frame
At start of treatment
Secondary Outcome Measure Information:
Title
Healing of anal fistula after treatment
Description
Clinical healing defined as closure of the internal and external fistula opening and no discharge evaluated as success rate of the healing in (%)
Time Frame
6 months after last injection of autologous adipose tissue
Title
Evaluation of fistula healing after treatment
Description
A combination of Clinical and MRI healing defined as closure of the internal and external fistula opening and no discharge and no fluid filled fistula tracts on evaluated as success rate of the healing in (%)
Time Frame
6 months after last injection of autologous adipose tissue
Title
Functional gastroenterological outcome after treatment
Description
Anal continence evaluated as the St. Mark's Score (0-24)
Time Frame
6 months after last injection of autologous adipose tissue
Title
Defecation disorder evaluation after treatment
Description
Defecation disorders evaluated as Altomare Obstructed Defecation Score (0-31)
Time Frame
6 months after last injection of autologous adipose tissue
Title
Functional urological outcome after treatment
Description
Urinary incontinence evaluated as ICIQ-UI-SF (0-21)
Time Frame
6 months after last injection of autologous adipose tissue
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
high trans-sphincteric fistulas
fistula confirmed and classified by an MRI.
seton (> 6 weeks) prior to fat injection
informed, written consent.
Exclusion Criteria:
Anovaginal fistula
Active sepsis
IBD, immunodeficiency, prior pelvic irradiation and malignancy
Insulin dependent diabetes
More than 4 prior attempts of fistula closure
Tobacco smoking or nicotine substitution 8 weeks prior to fat injection.
Pregnancy
Psychiatric disorders
BMI ≥ 35 or BMI<20
Active tuberculosis
Patient less than 18 years
Unable to undergo MRI
12. IPD Sharing Statement
Citations:
PubMed Identifier
34819138
Citation
Tencerova M, Lundby L, Buntzen S, Norderval S, Hougaard HT, Pedersen BG, Kassem M. Molecular differences of adipose-derived mesenchymal stem cells between non-responders and responders in treatment of transphincteric perianal fistulas. Stem Cell Res Ther. 2021 Nov 24;12(1):586. doi: 10.1186/s13287-021-02644-8.
Results Reference
derived
Learn more about this trial
Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas
We'll reach out to this number within 24 hrs